381 related articles for article (PubMed ID: 36189265)
1. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
2. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
3. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
Mazumder A; Darji K; Smith K; Guo M
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
[TBL] [Abstract][Full Text] [Related]
4. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
Palla AR; Smith E; Doll D
Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
[TBL] [Abstract][Full Text] [Related]
5. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
6. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
7. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
9. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
10. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
[TBL] [Abstract][Full Text] [Related]
11. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
[TBL] [Abstract][Full Text] [Related]
12. Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.
Olsen E; Svoboda SA; Saikaly SK; Missall TA; Motaparthi K
Cureus; 2023 Aug; 15(8):e43230. PubMed ID: 37692698
[TBL] [Abstract][Full Text] [Related]
13. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
Front Oncol; 2019; 9():1033. PubMed ID: 31649889
[No Abstract] [Full Text] [Related]
14. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
Alvarado SM; Weston G; Murphy MJ; Stewart CL
J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
[TBL] [Abstract][Full Text] [Related]
16. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract][Full Text] [Related]
17. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
Grimaux X; Delva R; Jadaud E; Croue A
Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
[No Abstract] [Full Text] [Related]
19. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
20. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]